Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.64 |
| ▸ | RAF1 | P04049 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454653 | 0.83 | EGFR (0.71) | MAP2K1SRCEGFRERBB2RET | |
| SCHEMBL4449038 | 0.80 | MAP2K1 (0.62) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL6994088 | 0.77 | EGFR (0.51) | MAP2K1SRCEGFRERBB2RET | |
| SCHEMBL4451083 | 0.77 | MAP2K1 (0.64) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL4445202 | 0.75 | SRC (0.48) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL4443460 | 0.75 | EGFR (0.71) | MAP2K1SRCEGFRERBB2RET | |
| SCHEMBL4447098 | 0.74 | MAP2K1 (0.64) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL2984975 | 0.73 | PRKCQ (0.78) | — | |
| SCHEMBL2985945 | 0.72 | PRKCQ (0.59) | ROCK2ROCK1KDR | |
| SCHEMBL4247140 | 0.72 | PRKCQ (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | claimed |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| WO-2017103931-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959979-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | MAP2K1 490/4885RAF1 185/4885SRC 290/4885 |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | MAP2K1 490/4885RAF1 185/4885SRC 290/4885 |
| US-10646465-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | MAP2K1 490/4885RAF1 185/4885SRC 290/4885 |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | MAP2K1 490/4885RAF1 185/4885SRC 290/4885 |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | MAP2K1 490/4885RAF1 185/4885SRC 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.